Calcitonin gene-related peptide (CGRP): A new target for migraine

Annual Review of Pharmacology and Toxicology

Volumn 55, Issue , 2015, Pages 533-552

  Russo, Andrew F ^a,b,c  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Neuromodulation; Neuropeptide; Photophobia; Sensitization; Trigeminovasculature

Indexed keywords

CALCITONIN GENE RELATED PEPTIDE; CALCITONIN GENE RELATED PEPTIDE RECEPTOR; CALCITONIN GENE RELATED PEPTIDE RECEPTOR ANTAGONIST; MONOCLONAL ANTIBODY; RECEPTOR ACTIVITY MODIFYING PROTEIN 1; ANALGESIC AGENT;

AVERSION; CENTRAL NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM SENSITIZATION; DISULFIDE BOND; EPIGENETICS; HUMAN; MIGRAINE; NEUROGENIC INFLAMMATION; NEUROMODULATION; NONHUMAN; PATHOGENESIS; PHOTOPHOBIA; PRIORITY JOURNAL; REVIEW; SENSORY STIMULATION; SPREADING CORTICAL DEPRESSION; SYNAPTIC TRANSMISSION; VASODILATATION; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG DESIGN; DRUG EFFECTS; EPISTASIS; GENETIC EPIGENESIS; GENETICS; IMMUNOLOGY; METABOLISM; MIGRAINE DISORDERS; MOLECULARLY TARGETED THERAPY; NERVE TRACT; NOCICEPTION; PAIN THRESHOLD; PATHOPHYSIOLOGY; PROCEDURES; SIGNAL TRANSDUCTION;

ANALGESICS; ANIMALS; ANTIBODIES, MONOCLONAL; CALCITONIN GENE-RELATED PEPTIDE; DRUG DESIGN; EPIGENESIS, GENETIC; EPISTASIS, GENETIC; HUMANS; MIGRAINE DISORDERS; MOLECULAR TARGETED THERAPY; NEURAL PATHWAYS; PAIN PERCEPTION; PAIN THRESHOLD; RECEPTORS, CALCITONIN GENE-RELATED PEPTIDE; SIGNAL TRANSDUCTION;

EID: 84920824222     PISSN: 03621642     EISSN: 15454304     Source Type: Book Series    
DOI: 10.1146/annurev-pharmtox-010814-124701     Document Type: Review

References (155)

1. Goadsby PJ, Lipton RB, Ferrari MD. 2002. Migraine-current understanding and treatment. N. Engl. J. Med. 346:257-70
2. Charles A. 2013. The evolution of a migraine attack - a review of recent evidence. Headache 53:413-19
3. de Tommaso M, Ambrosini A, Brighina F, Coppola G, Perrotta A, et al. 2014. Altered processing of sensory stimuli in patients with migraine. Nat. Rev. Neurol. 10:144-55
4. HeadacheClassif. Subcomm. Intl. Headache Society. 2004. The International Classification ofHeadache Disorders: 2nd edition. Cephalalgia 24(Suppl. 1):9-160
5. Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M. 2001. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache 41:646-57
6. Stewart WF, Wood C, Reed ML, Roy J, Lipton RB, AMPP Advis. Group. 2008. Cumulative lifetime migraine incidence in women and men. Cephalalgia 28:1170-78
7. Hawkins K, Wang S, Rupnow M. 2008. Direct cost burden among insuredUS employees with migraine. Headache 48:553-63
8. Menken M, Munsat TL, Toole JF. 2000. The Global Burden of Disease Study: implications for neurology. Arch. Neurol. 57:418-20
9. Loder E. 2010. Triptan therapy in migraine. N. Engl. J. Med. 363:63-70
10. Diener HC, Lampl C, Reimnitz P, Voelker M. 2006. Aspirin in the treatment of acute migraine attacks. Expert Rev. Neurother. 6:563-73
11. Diener HC, Dodick DW, Aurora SK, Turkel CC, DeGryse RE, et al. 2010. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia 30:804-14
12. Tfelt-Hansen P, Olesen J. 2012. Taking the negative view of current migraine treatments: the unmet needs. CNS Drugs 26:375-82
13. Levy D, Burstein R. 2011. The vascular theory of migraine: leave it or love it? Ann. Neurol. 69:600-1
14. Goadsby PJ. 2009. The vascular theory of migraine- A great story wrecked by the facts. Brain 132:6-7
15. Brennan KC, Charles A. 2010. An update on the blood vessel in migraine. Curr. Opin. Neurol. 23:266-74
16. Asghar MS, Hansen AE, Amin FM, van der Geest RJ, Koning P, et al. 2011. Evidence for a vascular factor in migraine. Ann. Neurol. 69:635-45
17. Ashina M. 2012. Vascular changes have a primary role in migraine. Cephalalgia 32:428-30
18. Charles A. 2012. Migraine is not primarily a vascular disorder. Cephalalgia 32:431-32
19. Raddant AC, Russo AF. 2011. Calcitonin gene-related peptide in migraine: intersection of peripheral inflammation and central modulation. Expert Rev. Mol. Med. 13:e36
20. Messlinger K. 2009. Migraine: Where and how does the pain originate? Exp. Brain Res. 196:179-93
21. Pietrobon D, Striessnig J. 2003. Neurobiology of migraine. Nat. Rev. Neurosci. 4:386-98
22. Bolay H, Reuter U, Dunn AK, Huang Z, Boas DA, Moskowitz MA. 2002. Intrinsic brain activity triggers trigeminal meningeal afferents in a migraine model. Nat. Med. 8:136-42
23. Lambert GA. 2010. The lack of peripheral pathology in migraine headache. Headache 50:895-908
24. Eftekhari S, Salvatore CA, Calamari A, Kane SA, Tajti J, Edvinsson L. 2010. Differential distribution of calcitonin gene-related peptide and its receptor components in the human trigeminal ganglion. Neuroscience 169:683-96
25. Amara SG, Jonas V, Rosenfeld MG, Ong ES, Evans RM. 1982. Alternative RNA processing in calcitonin gene expression generates mRNAs encoding different polypeptide products. Nature 298:240-44
26. Rosenfeld MG, Mermod JJ, Amara SG, Swanson LW, Sawchenko PE, et al. 1983. Production of a novel neuropeptide encoded by the calcitonin gene via tissue-specific RNA processing. Nature 304:129-35
27. Russo AF, Dickerson IM. 2006. CGRP: A multifunctional neuropeptide. In Handbook of Neurochemistry and Molecular Neurobiology, ed. A Lajtha, R Lim, pp. 391-426. New York: Springer
28. van Rossum D, Hanisch UK, Quirion R. 1997. Neuroanatomical localization, pharmacological characterization and functions ofCGRP, related peptides and their receptors. Neurosci. Biobehav. Rev. 21:649-78
29. Recober A, Russo AF. 2009. Calcitonin gene-related peptide: an update on the biology. Curr. Opin. Neurol. 22:241-46
30. Benarroch EE. 2011. CGRP: sensory neuropeptide with multiple neurologic implications. Neurology 77:281-87
31. Kaiser EA, Russo AF. 2013. CGRP andmigraine: could PACAP play a role too? Neuropeptides 47:451-61
32. Breeze AL, Harvey TS, Bazzo R, Campbell ID. 1991. Solution structure of human calcitonin generelated peptide by 1H NMR and distance geometry with restrained molecular dynamics. Biochemistry 30:575-82
33. Poyner DR, Sexton PM, Marshall I, Smith DM, Quirion R, et al. 2002. International Union of Pharmacology. XXXII. Themammalian calcitonin gene-related peptides, adrenomedullin, amylin, and calcitonin receptors. Pharmacol. Rev. 54:233-46
34. Amara SG, Arriza JL, Leff SE, Swanson LW, Evans RM, Rosenfeld MG. 1985. Expression in brain of a messenger RNA encoding a novel neuropeptide homologous to calcitonin gene-related peptide. Science 229:1094-97
35. Mulderry PK, Ghatei MA, Spokes RA, Jones PM, Pierson AM, et al. 1988. Differential expression of α- CGRP and β-CGRP by primary sensory neurons and enteric autonomic neurons of the rat. Neuroscience 25:195-205
36. Russo AF, Nelson C, Roos BA, Rosenfeld MG. 1988. Differential regulation of the coexpressed calcitonin/β-CGRP and β-CGRP neuroendocrine genes. J. Biol. Chem. 263:5-8
37. Sexton PM, Christopoulos G, Christopoulos A, Nylen ES, Snider RH Jr, Becker KL. 2008. Procalcitonin has bioactivity at calcitonin receptor family complexes: potential mediator implications in sepsis. Crit. Care Med. 36:1637-40
38. Zhang Z, Dickerson IM, Russo AF. 2006. Calcitonin gene-related peptide receptor activation by receptor activity-modifying protein-1 gene transfer to vascular smooth muscle cells. Endocrinology 147:1932-40
39. Zhang Z, Winborn CS, Marquez de Prado B, Russo AF. 2007. Sensitization of calcitonin gene-related peptide receptors by receptor activity-modifying protein-1 in the trigeminal ganglion. J. Neurosci. 27:2693-703
40. Heroux M, Hogue M, Lemieux S, Bouvier M. 2007. Functional calcitonin gene-related peptide receptors are formed by the asymmetric assembly of a calcitonin receptor-like receptor homo-oligomer and a monomer of receptor activity-modifying protein-1. J. Biol. Chem. 282:31610-20
41. Walker CS, Conner AC, Poyner DR, Hay DL. 2010. Regulation of signal transduction by calcitonin gene-related peptide receptors. Trends Pharmacol. Sci. 31:476-83
42. Archbold JK, Flanagan JU, Watkins HA, Gingell JJ, Hay DL. 2011. Structural insights into RAMP modification of secretin family G protein-coupled receptors: implications for drug development. Trends Pharmacol. Sci. 32:591-600
43. ter Haar E, Koth CM, Abdul-Manan N, Swenson L, Coll JT, et al. 2010. Crystal structure of the ectodomain complex of the CGRP receptor, a class-B GPCR, reveals the site of drug antagonism. Structure 18:1083-93
44. Walker CS, Hay DL. 2013. CGRP in the trigeminovascular system: A role for CGRP, adrenomedullin and amylin receptors? Br. J. Pharmacol. 170:1293-307
45. Petersen KA, Birk S, Kitamura K, Olesen J. 2009. Effect of adrenomedullin on the cerebral circulation: relevance to primary headache disorders. Cephalalgia 29:23-30
46. Hay DL, Poyner DR, Quirion R. 2008. International Union of Pharmacology. LXIX. Status of the calcitonin gene-related peptide subtype 2 receptor. Pharmacol. Rev. 60:143-45
47. Villalon CM, Olesen J. 2009. The role of CGRP in the pathophysiology of migraine and efficacy of CGRP receptor antagonists as acute antimigraine drugs. Pharmacol. Ther. 124:309-23
48. Ho TW, Edvinsson L, Goadsby PJ. 2010. CGRP and its receptors provide new insights into migraine pathophysiology. Nat. Rev. Neurol. 6:573-82
49. Goadsby PJ, Edvinsson L, Ekman R. 1990. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann. Neurol. 28:183-87
50. Tfelt-Hansen P, Le H. 2009. Calcitonin gene-related peptide in blood: Is it increased in the external jugular vein during migraine and cluster headache? A review. J. Headache Pain 10:137-43
51. Ashina M, Bendtsen L, Jensen R, Schifter S, Olesen J. 2000. Evidence for increased plasma levels of calcitonin gene-related peptide in migraine outside of attacks. Pain 86:133-38
52. Cernuda-Moroll on E, Larrosa D, Ramon C, Vega J, Martnez-Camblor P, Pascual J. 2013. Interictal increase of CGRP levels in peripheral blood as a biomarker for chronic migraine. Neurology 81:1191-96
53. Tvedskov JF, Lipka K, Ashina M, Iversen HK, Schifter S, Olesen J. 2005. No increase of calcitonin gene-related peptide in jugular blood during migraine. Ann. Neurol. 58:561-68
54. Lassen LH, Haderslev PA, Jacobsen VB, Iversen HK, Sperling B, Olesen J. 2002. CGRP may play a causative role in migraine. Cephalalgia 22:54-61
55. Hansen JM, Hauge AW, Olesen J, Ashina M. 2010. Calcitonin gene-related peptide triggers migrainelike attacks in patients with migraine with aura. Cephalalgia 30:1179-86
56. Petersen KA, Lassen LH, Birk S, Lesko L, Olesen J. 2005. BIBN4096BS antagonizes humanα-calcitonin gene related peptide-induced headache and extracerebral artery dilatation. Clin. Pharmacol. Ther. 77:202-13
57. Recober A, Kuburas A, Zhang Z, Wemmie JA, Anderson MG, Russo AF. 2009. Role of calcitonin gene-related peptide in light-aversive behavior: implications for migraine. J. Neurosci. 29:8798-804
58. Russo AF, Kuburas A, Kaiser EA, Raddant AC, Recober A. 2009. A potential preclinical migrainemodel: CGRP-sensitized mice. Mol. Cell Pharmacol. 1:264-70
59. Schytz HW, Schoonman GG, Ashina M. 2010. What have we learnt from triggering migraine? Curr. Opin. Neurol. 23:259-65
60. Edvinsson L. 2008. CGRPblockers in migraine therapy:Where do they act? Br. J. Pharmacol. 155:967-69
61. Tfelt-Hansen P, Olesen J. 2011. Possible site of action of CGRP antagonists in migraine. Cephalalgia 31:748-50
62. Fischer MJM, Koulchitsky S, Messlinger K. 2005. The nonpeptide calcitonin gene-related peptide receptor antagonist BIBN4096BS lowers the activity of neurons with meningeal input in the rat spinal trigeminal nucleus. J. Neurosci. 25:5877-83
63. Olesen J, Diener HC, Husstedt IW, Goadsby PJ, Hall D, et al. 2004. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N. Engl. J. Med. 350:1104-10
64. Doods H, Arndt K, Rudolf K, Just S. 2007. CGRPantagonists: unravelling the role ofCGRPin migraine. Trends Pharmacol. Sci. 28:580-87
65. Bigal ME, Walter S, Rapoport AM. 2013. Calcitonin gene-related peptide (CGRP) and migraine: current understanding and state of development. Headache 53:1230-44
66. Peroutka SJ. 2014. Calcitonin gene-related peptide targeted immunotherapy for migraine: progress and challenges in treating headache. BioDrugs 28:237-44
67. Ho TW, Mannix LK, Fan X, Assaid C, Furtek C, et al. 2008. Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine. Neurology 70:1304-12
68. Kam-Hansen S, Jakubowski M, Kelley JM, Kirsch I, Hoaglin DC, et al. 2014. Altered placebo and drug labeling changes the outcome of episodic migraine attacks. Sci. Translational Med. 6:218ra5
69. Connor KM, Shapiro RE, Diener HC, Lucas S, Kost J, et al. 2009. Randomized, controlled trial of telcagepant for the acute treatment of migraine. Neurology 73:970-77
70. Ho TW, Ferrari MD, Dodick DW, Galet V, Kost J, et al. 2008. Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: A randomised, placebo-controlled, parallel-treatment trial. Lancet 372:2115-23
71. Connor KM, Aurora SK, Loeys T, Ashina M, Jones C, et al. 2011. Long-term tolerability of telcagepant for acute treatment of migraine in a randomized trial. Headache 51:73-84
72. Cui XP, Ye JX, Lin H, Mu JS, Lin M. 2013. Efficacy, safety, and tolerability of telcagepant in the treatment of acute migraine: A meta-analysis. Pain Pract. doi: 10. 1111/papr. 12158
73. Ho TW, Connor KM, Zhang Y, Pearlman E, Koppenhaver J, et al. 2014. Randomized controlled trial of the CGRP receptor antagonist telcagepant for migraine prevention. Neurology 83:958-66
74. Hewitt DJ, Aurora SK, Dodick DW, Goadsby PJ, Ge YJ, et al. 2011. Randomized controlled trial of the CGRP receptor antagonist MK-3207 in the acute treatment of migraine. Cephalalgia 31:712-22
75. Diener HC, Barbanti P, Dahlof C, Reuter U, Habeck J, Podhorna J. 2011. BI 44370 TA, an oral CGRP antagonist for the treatment of acute migraine attacks: results from a phase II study. Cephalalgia 31:573-84
76. Marcus R, Goadsby PJ, Dodick D, Stock D, Manos G, Fischer TZ. 2014. BMS-927711 for the acute treatment of migraine: A double-blind, randomized, placebo controlled, dose-ranging trial. Cephalalgia 34:114-25
77. Miranda LP, Shi L, Holder JR, Wright M, Gegg CV, et al. 2013. Peptide antagonists of the calcitonin gene-related peptide (CGRP) receptor with improved pharmacokinetics and pharmacodynamics. Biopolymers 100:422-30
78. Joshi P, Anderson C, Binch H, Hadida S, Yoo S, et al. 2014. Identification of potent CNS-penetrant thiazolidinones as novel CGRP receptor antagonists. Bioorg. Med. Chem. Lett. 24:845-49
79. Goadsby P, Dodick D, Silberstein S, Lipton R, Olesen J, et al. 2014. Randomized, double-blind, placebocontrolled trial of ALD403, an anti-CGRP peptide antibody in the prevention of frequent episodic migraine. Presented at 66th Annu. Meet. Am. Acad. Neurol., April 26-May 3, Philadelphia, PA
80. Dodick DW, Goadsby PJ, Spierings EL, Scherer JC, Sweeney SP, Grayzel DS. 2014. Safety and efficacy of LY2951742, amonoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: A phase 2, randomised, double-blind, placebo-controlled study. Lancet Neurol. 13:885-92
81. Benschop RJ, Collins EC, Darling RJ, Allan BW, Leung D, et al. 2014. Development of a novel antibody to calcitonin gene-related peptide for the treatment of osteoarthritis-related pain. Osteoarthr. Cartil. 22:578-85
82. Bullock CM, Kelly S. 2013. Calcitonin gene-related peptide receptor antagonists: beyond migraine pain- A possible analgesic strategy for osteoarthritis? Curr. Pain Headache Rep. 17:375
83. Bigal ME, Escandon R, Bronson M, Walter S, Sudworth M, et al. 2013. Safety and tolerability of LBR- 101, a humanized monoclonal antibody that blocks the binding of CGRP to its receptor: results of the Phase 1 program. Cephalalgia 34:483-92
84. Smillie SJ, King R, Kodji X, Outzen E, Pozsgai G, et al. 2014. An ongoing role of α-calcitonin generelated peptide as part of a protective network against hypertension, vascular hypertrophy, and oxidative stress. Hypertension 63:1056-62
85. Woods IG, Schoppik D, Shi VJ, Zimmerman S, Coleman HA, et al. 2014. Neuropeptidergic signaling partitions arousal behaviors in zebrafish. J. Neurosci. 34:3142-60
86. Brain SD, Grant AD. 2004. Vascular actions of calcitonin gene-related peptide and adrenomedullin. Physiol. Rev. 84:903-34
87. Olesen J, Burstein R, Ashina M, Tfelt-Hansen P. 2009. Origin of pain in migraine: evidence for peripheral sensitisation. Lancet Neurol. 8:679-90
88. Levy D, Burstein R, Kainz V, Jakubowski M, Strassman AM. 2007. Mast cell degranulation activates a pain pathway underlying migraine headache. Pain 130:166-76
89. Strassman AM, Raymond SA, Burstein R. 1996. Sensitization of meningeal sensory neurons and the origin of headaches. Nature 384:560-64
90. Bernstein C, Burstein R. 2012. Sensitization of the trigeminovascular pathway: perspective and implications to migraine pathophysiology. J. Clin. Neurol. 8:89-99
91. Ottosson A, Edvinsson L. 1997. Release of histamine from dural mast cells by substance P and calcitonin gene-related peptide. Cephalalgia 17:166-74
92. Theoharides TC, Donelan J, Kandere-Grzybowska K, Konstantinidou A. 2005. The role of mast cells in migraine pathophysiology. Brain Res. Rev. 49:65-76
93. Lennerz JK, Ruhle V, Ceppa EP, Neuhuber WL, Bunnett NW, et al. 2008. Calcitonin receptor-like receptor (CLR), receptor activity-modifying protein 1 (RAMP1), and calcitonin gene-related peptide (CGRP) immunoreactivity in the rat trigeminovascular system: differences between peripheral and central CGRP receptor distribution. J. Comp. Neurol. 507:1277-99
94. Eftekhari S1, Warfvinge K, Blixt FW, Edvinsson L. 2013. Differentiation of nerve fibers storing CGRP and CGRP receptors in the peripheral trigeminovascular system. J. Pain 14:1289-303
95. Thalakoti S, Patil VV, Damodaram S, Vause CV, Langford LE, et al. 2007. Neuron-glia signaling in trigeminal ganglion: implications for migraine pathology. Headache 47:1008-23; discussion 24-25
96. Capuano A, DeCorato A, Lisi L, Tringali G, Navarra P, Dello Russo C. 2009. Proinflammatory-activated trigeminal satellite cells promote neuronal sensitization: relevance for migraine pathology. Mol. Pain 5:43
97. De Corato A, Lisi L, Capuano A, Tringali G, Tramutola A, et al. 2011. Trigeminal satellite cells express functional calcitonin gene-related peptide receptors, whose activation enhances interleukin-1β proinflammatory effects. J. Neuroimmunol. 237:39-46
98. Diener HC. 2003. RPR100893, a substance-P antagonist, is not effective in the treatment of migraine attacks. Cephalalgia 23:183-85
99. Levy D, Burstein R, Strassman AM. 2005. Calcitonin gene-related peptide does not excite or sensitize meningeal nociceptors: implications for the pathophysiology of migraine. Ann. Neurol. 58:698-705
100. Sixt ML, Messlinger K, Fischer MJM. 2009. Calcitonin gene-related peptide receptor antagonist olcegepant acts in the spinal trigeminal nucleus. Brain 132:3134-41
101. Storer RJ, Akerman S, Goadsby PJ. 2004. Calcitonin gene-related peptide (CGRP)modulates nociceptive trigeminovascular transmission in the cat. Br. J. Pharmacol. 142:1171-81
102. Giniatullin R, Nistri A, Fabbretti E. 2008. Molecular mechanisms of sensitization of pain-transducing P2X3 receptors by the migraine mediators CGRP and NGF. Mol. Neurobiol. 37:83-90
103. Simonetti M, Giniatullin R, Fabbretti E. 2008. Mechanisms mediating the enhanced gene transcription of P2X3 receptor by calcitonin gene-related peptide in trigeminal sensory neurons. J. Biol. Chem. 283:18743-52
104. Souslova V, Cesare P, Ding Y, Akopian AN, Stanfa L, et al. 2000. Warm-coding deficits and aberrant inflammatory pain in mice lacking P2X3 receptors. Nature 407:1015-17
105. Coull JA, Beggs S, Boudreau D, Boivin D, Tsuda M, et al. 2005. BDNF from microglia causes the shift in neuronal anion gradient underlying neuropathic pain. Nature 438:1017-21
106. Fischer M, Wille G, Klien S, Shanib H, Holle D, et al. 2012. Brain-derived neurotrophic factor in primary headaches. J. Headache Pain 13:469-75
107. Bowen EJ, Schmidt TW, Firm CS, Russo AF, Durham PL. 2006. Tumor necrosis factor-α stimulation of calcitonin gene-related peptide expression and secretion from rat trigeminal ganglion neurons. J. Neurochem. 96:65-77
108. Tajti J, Uddman R, Moller S, Sundler F, Edvinsson L. 1999. Messenger molecules and receptor mRNA in the human trigeminal ganglion. J. Auton. Nerv. Syst. 76:176-83
109. Edvinsson L, Eftekhari S, Salvatore CA, Warfvinge K. 2011. Cerebellar distribution of calcitonin generelated peptide (CGRP) and its receptor components calcitonin receptor-like receptor (CLR) and receptor activity modifying protein 1 (RAMP1) in rat. Mol. Cell. Neurosci. 46:333-39
110. Seiler K, Nusser JI, Lennerz JK, Neuhuber WL, Messlinger K. 2013. Changes in calcitonin gene-related peptide (CGRP) receptor component and nitric oxide receptor (sGC) immunoreactivity in rat trigeminal ganglion following glyceroltrinitrate pretreatment. J. Headache Pain 14:74
111. Hay DL, Poyner DR, Sexton PM. 2006. GPCR modulation by RAMPs. Pharmacol. Ther. 109:173-97
112. Russo AF, Recober A. 2013. Unanswered questions in headache: So what is photophobia, anyway? Headache 53:1677-78
113. Noseda R, Burstein R. 2011. Advances in understanding the mechanisms of migraine-type photophobia. Curr. Opin. Neurol. 24:197-202
114. Digre KB, Brennan KC. 2012. Shedding light on photophobia. J. Neuroophthalmol. 32:68-81
115. Recober A, Kaiser EA, Kuburas A, Russo AF. 2010. Induction of multiple photophobic behaviors in a transgenic mouse sensitized to CGRP. Neuropharmacology 58:156-65
116. Kaiser EA, Kuburas A, Recober A, Russo AF. 2012. Modulation of CGRP-induced light aversion in wild-type mice by a 5-HT1B/D agonist. J. Neurosci. 32:15439-49
117. Rossi HL, Recober A. 2014. Photophobia in primary headaches. Headache. In press
118. Noseda R, Kainz V, Jakubowski M, Gooley JJ, Saper CB, et al. 2010. Aneuralmechanism for exacerbation of headache by light. Nat. Neurosci. 13:239-45
119. Maleki N, Becerra L, Upadhyay J, Burstein R, Borsook D. 2012. Direct optic nerve pulvinar connections defined by diffusionMRtractography in humans: implications for photophobia. Hum. BrainMapp. 33:75-88
120. Summ O, Charbit AR, Andreou AP, Goadsby PJ. 2010. Modulation of nocioceptive transmission with calcitonin gene-related peptide receptor antagonists in the thalamus. Brain 133:2540-48
121. Noseda R, Kainz V, Borsook D, Burstein R. 2014. Neurochemical pathways that converge on thalamic trigeminovascular neurons: potential substrate for modulation of migraine by sleep, food intake, stress and anxiety. PLOS ONE 9:e103929
122. Marvizon JCG, Perez OA, Song B, Chen W, Bunnett NW, et al. 2007. Calcitonin receptor-like receptor and receptor activitymodifying protein 1 in the rat dorsal horn: localization in glutamatergic presynaptic terminals containing opioids and adrenergic β2C receptors. Neuroscience 148: 250-65
123. Seybold VS. 2009. The role of peptides in central sensitization. Handb. Exp. Pharmacol. 194:451-91
124. Fischer MJM. 2010. Calcitonin gene-related peptide receptor antagonists for migraine. Expert Opin. Investig. Drugs 19:815-23
125. Gu XL, Yu LC. 2007. The colocalization of CGRP receptor and AMPA receptor in the spinal dorsal horn neuron of rat: A morphological and electrophysiological study. Neurosci. Lett. 414:237-41
126. Marquez de Prado B, Hammond DL, Russo AF. 2009. Genetic enhancement of calcitonin gene-related peptide-induced central sensitization to mechanical stimuli in mice. J. Pain 10:992-1000
127. Rogoz K, Andersen HH, Kullander K, Lagerstrom MC. 2014. Glutamate, substance P, and calcitonin gene-related peptide cooperate in inflammation-induced heat hyperalgesia. Mol. Pharmacol. 85:322-34
128. Sun RQ, Tu YJ, Lawand NB, Yan JY, Lin Q, Willis WD. 2004. Calcitonin gene-related peptide receptor activation produces PKA- and PKC-dependent mechanical hyperalgesia and central sensitization. J. Neurophysiol. 92:2859-66
129. Sink KS, Walker DL, Yang Y, Davis M. 2011. Calcitonin gene-related peptide in the bed nucleus of the stria terminalis produces an anxiety-like pattern of behavior and increases neural activation in anxietyrelated structures. J. Neurosci. 31:1802-10
130. Neugebauer V, Li W, Bird GC, Han JS. 2004. The amygdala and persistent pain. Neuroscientist 10:221-34
131. Han JS, Adwanikar H, Li Z, Ji G, Neugebauer V. 2010. Facilitation of synaptic transmission and pain responses by CGRP in the amygdala of normal rats. Mol. Pain 6:10
132. Huang Y, Brodda-Jansen G, Lundeberg T, Yu LC. 2000. Anti-nociceptive effects of calcitonin generelated peptide in nucleus raphe magnus of rats: an effect attenuated by naloxone. Brain Res. 873:54-59
133. Charbit AR, Akerman S, Holland PR, Goadsby PJ. 2009. Neurons of the dopaminergic/calcitonin generelated peptide A11 cell group modulate neuronal firing in the trigeminocervical complex: an electrophysiological and immunohistochemical study. J. Neurosci. 29:12532-41
134. Charles AC, Baca SM. 2013. Cortical spreading depression and migraine. Nat. Rev. Neurol. 9:637-44
135. Zhang X, Levy D, Noseda R, Kainz V, Jakubowski M, Burstein R. 2010. Activation of meningeal nociceptors by cortical spreading depression: implications for migraine with aura. J. Neurosci. 30:8807-14
136. Zhang X, Levy D, Kainz V, Noseda R, Jakubowski M, Burstein R. 2011. Activation of central trigeminovascular neurons by cortical spreading depression. Ann. Neurol. 69:855-65
137. Levy D. 2010. Migraine pain and nociceptor activation-where do we stand? Headache 50:909-16
138. Kosaras B, Jakubowski M, Kainz V, Burstein R. 2009. Sensory innervation of the calvarial bones of the mouse. J. Comp. Neurol. 515:331-48
139. Reuter U, Weber JR, Gold L, Arnold G, Wolf T, et al. 1998. Perivascular nerves contribute to cortical spreading depression-associated hyperemia in rats. Am. J. Physiol. 274:H1979-87
140. Colonna DM, Meng W, Deal DD, Busija DW. 1994. Calcitonin gene-related peptide promotes cerebrovascular dilation during cortical spreading depression in rabbits. Am. J. Physiol. 266:H1095-102
141. Wahl M, Schilling L, Parsons AA, Kaumann A. 1994. Involvement of calcitonin gene-related peptide (CGRP) and nitric oxide (NO) in the pial artery dilatation elicited by cortical spreading depression. Brain Res. 637:204-10
142. Tozzi A, de Iure A, Di Filippo M, Costa C, Caproni S, et al. 2012. Critical role of calcitonin gene-related peptide receptors in cortical spreading depression. Proc. Natl. Acad. Sci. USA 109:18985-90
143. Viggiano A, Viggiano E, Valentino I, Monda M, Viggiano A, De Luca B. 2011. Cortical spreading depression affects reactive oxygen species production. Brain Res. 1368:11-18
144. Shatillo A, Koroleva K, Giniatullina R, Naumenko N, Slastnikova AA, et al. 2013. Cortical spreading depression induces oxidative stress in the trigeminal nociceptive system. Neuroscience 253:341-49
145. Raddant AC, Russo AF. 2014. Reactive oxygen species induce procalcitonin expression in trigeminal ganglia glia. Headache 54:472-84
146. Park KY, Fletcher JR, Raddant AC, Russo AF. 2011. Epigenetic regulation of the calcitonin gene-related peptide gene in trigeminal glia. Cephalalgia 31:614-24
147. Anttila V, Winsvold BS, Gormley P, Kurth T, Bettella F, et al. 2013. Genome-wide meta-analysis identifies new susceptibility loci for migraine. Nat. Genet. 45:912-17
148. Esserlind AL, Christensen AF, Le H, Kirchmann M, Hauge AW, et al. 2013. Replication and metaanalysis of common variants identifies a genome-wide significant locus in migraine. Eur. J. Neurol. 20:765-72
149. Brennan KC, Bates EA, Shapiro RE, Zyuzin J, Hallows WC, et al. 2013. Casein kinase Iδ mutations in familial migraine and advanced sleep phase. Sci. Translational Med. 5:183ra56
150. Eising E, de Vries B, Ferrari MD, Terwindt GM, van den Maagdenberg AMJM. 2013. Pearls and pitfalls in genetic studies of migraine. Cephalalgia 33:614-25
151. Menon S, Buteri J, Roy B, Murrell M, Quinlan S, et al. 2011. Association study of calcitonin gene-related polypeptide-alpha (CALCA) gene polymorphism with migraine. Brain Res. 1378:119-24
152. Jansen-Olesen I, Baun M, Amrutkar DV, Ramachandran R, Christophersen DV, Olesen J. 2014. PACAP- 38 but not VIP induces release of CGRP from trigeminal nucleus caudalis via a receptor distinct from the PAC1 receptor. Neuropeptides 48:53-64
153. Eising E, Datson NA, van den Maagdenberg AMJM, Ferrari MD. 2013. Epigenetic mechanisms in migraine: A promising avenue? BMC Med. 11:26
154. Cutrer FM, Limmroth V, Moskowitz MA. 1997. Possible mechanisms of valproate in migraine prophylaxis. Cephalalgia 17:93-100
155. Nalivaeva NN, Belyaev ND, Turner AJ. 2009. Sodium valproate: an old drug with new roles. Trends Pharmacol. Sci. 30:509-14